Flatiron announces clinical decision support application through Epic’s App Orchard

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Flatiron Health announced the availability of its clinical decision support and pathways application, Flatiron Assist, in the App Orchard.

Flatiron Assist supports oncologists in selecting therapies in line with best clinical practices, including the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, and in identifying potentially relevant clinical trials.

The integrated regimen selection workflow allows clinicians to quickly confirm the clinical data needed to determine adherence to guidelines. Health system administrators can use the clinical data collected by this tool to streamline the prior authorization process, measure variation in care across a practice or health system, and report pathways compliance to payers.

“The rapidly evolving treatment landscape and increasing payer reporting requirements make it challenging for busy oncologists to efficiently get the best treatments to their patients,” James Hamrick, senior medical director, Flatiron Health, said in a statement. “Flatiron Assist is an EHR-integrated tool that puts the doctor and the patient at the forefront, enabling evidence-based treatment selection, efficient payer authorization, and insight into care patterns across practices and health systems.”

Available now in the App Orchard, Flatiron Assist is a SMART on FHIR application that will launch from the patient’s chart in Epic, eliminating the need for duplicate data entry outside the electronic medical record. Flatiron Assist pulls available demographics, diagnosis, and cancer-specific data, such as staging, from Epic and, based on those inputs, surfaces evidence-based therapy options and clinical trials for each patient. Once the oncologist chooses a treatment regimen in Flatiron Assist™, the selected regimen is automatically opened in Epic.

“Integrating NCCN’s recommendations into point-of-care apps like Flatiron Assist puts the latest evidence and multidisciplinary expert knowledge at the fingertips of oncologists everywhere,” Robert W. Carlson, CEO of NCCN, said in a statement. “NCCN Guidelines are the most frequently updated medical guidelines in any discipline; they should also be the most accessible. The convenience of Flatiron Assist can give doctors more time to engage in shared decision making in order to determine which guideline-concordant treatment plan offers the most benefit.”

Additional information is available here, and here.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login